Phases of clinical trials

Phases of clinical trials and medicine development. Four phases of clinical trials and medicine development exist and are defined below. Each of these definitions is a functional one and the terms are not defined on a strict chronological basis. An investigational medicine is often evaluated in two or more phases simultaneously in different clinical trials. Also, some clinical trials may overlap two different phases. 

Phase I, II, and III Trials An IND is submitted for each phase of clinical trial. Phases I to III. At any stage of the trial, the FDA has the authority to put clinical hold on the trial until deficiencies or safety issues are resolved. The Sponsor can request meetings with the FDA at various stages ... 

Part IV This is the clinical documentation. All phases of clinical trials must be carried out in accordance with GCP. The clinical data are pharmacodynamics, pharmacokinetics, clinical trials (including all individual data), and postmarketing experience. 

When all criteria are met, the optimized lead becomes a drug candidate. Typically, one in 100 000 HTS actives reaches this stage [20]. Following approval from regulatory authorities, drug candidates proceed to clinical trials. If all three phases of clinical trials prove successful, which only one in 10 candidate drugs [21] does, the compound is approved and becomes a launched (or marketed) drug. 

The extraordinary biological activity of epothilones has spurred interest of scientists around the world. Indeed, several epothilones and many derivatives are currently in different phases of clinical trials for the treatment of various forms of cancer. Also the synthetic community has given a great deal of attention to these remarkable compounds, probably more than to any other compound in the last ten years. This is not very surprising, because in comparison to paclitaxel (which until recently was one of the main success stories of natural products research), the epothilones have a relatively simple structure, which allows easier modification, and they display higher in vitro activity as well as better pharmacokinetic properties. 

Clinical success rates and attrition rates by phase of clinical trial for new drugs are important indicators of how effectively companies are utilising drug development resources. The proficiency with which this is done reflects a complex set of regulatory, economic and company-specific factors. Success rates differ by therapeutic class, and t)q)ically vary from about 28% success rate for an anti-infective compound to 12% for respiratory drugs. Table 9.3 shows the details. 

Research Ethics Committees (RECs) should be invited to review all materials used to recruit subjects for all phases of clinical trials, including, but not limited to ... 

Making prototypes and laboratory testing of polymer disks are projects that require limited cost and time duration. Certification by the FDA, on the other hand, is a long drawn out and costly process, where animal tests are followed by three phases of clinical trials, which have been described elsewhere (e.g. Suffness 1995). When the results are assessed and evaluated, a brand new product that costs more than 100 million can also run into many unforeseen problems, which makes many financiers very cautions. One of the biggest unknowns is who would pay for this costly new form of medication, and whether the medical insurance companies and Medicare would approve payment. This is the reason why so many information technology products, such as digital cameras and spreadsheets, are launched quickly, as they require much less capital to start and do not require FDA clearance. 

In less than 3 years the three phases of clinical trials were completed with more than 4000 patients enrolled. 

It often requires 4-6 years of clinical testing to accumulate all required data. Testing in humans is begun after sufficient acute and subacute animal toxicity studies have been completed. Chronic safety testing in animals is usually done concurrently with clinical trials. In each of the three formal phases of clinical trials, volunteers or patients must be informed of the investigational status of the... 

Many proactive QA measures can and should be installed during all phases of clinical trial activities, such as ensuring that assays used throughout the trials are properly developed and used clinical trial materials are adequately manufactured, packaged, and labeled appropriate communication between research personnel and other clinical departments is maintained and most important, creativity and flexibility are balanced with reasonable drug development timelines. 

The Federal Food, Drug and Cosmetic Act prohibits the shipment of a new drug into interstate commerce unless there exists for that drug an approved NDA or an effective IND application. Unlike certain European countries, such as Germany and the United Kingdom, the existence of an IND is required regardless of the proposed phase of clinical trial. Thus, even phase 1 trials to be conducted in the United States on volunteer subjects require the prior submission of an IND before that trial may be undertaken. 

The discovery of Taxol is a fruit of a National Cancer Institute (NCI)-sponsored project on identification of antitumor agents from natural resources. Bioassay-guided fractionation led to the isolation of this unique compound from Taxus bre-vifolia (pacific yew). Wani et al. also identified another famous antitumor natural product camptothecin. Unlike camptothecin, which was abandoned in the phase of clinical trial because of its severe toxicity, Taxol was almost discarded at the preliminary phase because it only exhibited moderate in vitro activity toward P388, a murine leukemia cell line that was used in the standard evaluation system by NCI researchers at that time. However, it was rescued by a subsequent finding of its strong and selective antitumor activities toward several solid tumors, and more... 

In the third stage, i.e., the various phases of clinical trials, pharmacokinetics is studied in detail in order to obtain the therapeutic index, to study drag-drag interactions, and to design dosage regimes. 

Clinical data, including the various phases of clinical trials conducted on the product. 

---